An international survey of the diagnosis, management, and treatment of hepatitis C in patients with end-stage renal disease

Experimental and Clinical Transplantation

Volumn 7, Issue 4, 2009, Pages 203-213

  Olson, Mira R ^a   Grewal, Kevin S ^a   Bingaman, Adam ^b   Zaki, Radi ^a   Stewart, Shelby ^a   Horton, John ^c   Araya, Victor ^a   Ortiz, Jorge ^a  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

^b TEXAS TRANSPLANT INSTITUTE   (United States)

^c Beaumont Medical Center

Author keywords

Dialysis; Interferon; Ribavirin; Transplantation

Indexed keywords

PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ARTICLE; DECISION MAKING; DIALYSIS; DRUG DOSE ESCALATION; HEALTH SURVEY; HEPATITIS C; HUMAN; KIDNEY DISEASE; KIDNEY DONOR; KIDNEY GRAFT; LIVER BIOPSY; MORTALITY; PHYSICIAN; QUESTIONNAIRE; UNITED STATES;

ANTIVIRAL AGENTS; BIOPSY; EVIDENCE-BASED MEDICINE; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HEPATITIS C; HUMANS; INFORMED CONSENT; INTERFERONS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; RIBAVIRIN; TISSUE DONORS; TREATMENT OUTCOME;

EID: 75649117860     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705-714.
2. Huang JF, Chuang WL, Dai CY, et al. Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link? J Intern Med. 2006;260(3):255-262.
3. Fissell RB, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2004;65(6):2335-2342.
4. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther. 2004;20(11-12):1271-1277.
5. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant. 2005;5(6):1452-1461.
6. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl. 2008;(109):S1-S99.
7. Strader DB,Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39(4):1147-1171. No abstract available. Erratum in: Hepatology. 2004;40(1):269.
8. Kalambokis G, Manousou P, Vibhakorn S, et al. Transjugular liver biopsy - indications, adequacy, quality of specimens, and complicationsa systematic review. J Hepatol. 2007;47(2):284-294.
9. Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Dialysis PatientsWith Chronic Hepatitis C. 2007 December 21, 2008 NCT00491244 (this study is currently recruiting participants).
10. Bucci JR, Matsumoto CS, Swanson SJ, et al. Donor hepatitis C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J Am Soc Nephrol. 2002;13(12):2974-2982.
11. Pereira BJ,Wright TL, Schmid CH, et al. Screening and confirmatory testing of cadaver organ donors for hepatitis C virus infection: a U.S. National Collaborative Study. Kidney Int. 1994;46(3):886-892.
12. Murray KF, Carithers RL Jr; AASLD. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology. 2005;41(6):1407-1432.